Inhalable Hsa-miR-30a-3p Liposomes Attenuate Pulmonary Fibrosis

Area of Science:

• Pulmonary Medicine
• Nanotechnology
• Molecular Biology

Background:

• Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with limited treatment options.
• Exosomes enriched with hsa-miR-30a-3p have shown therapeutic potential in pulmonary fibrosis models.
• This study explores hsa-miR-30a-3p as a standalone therapeutic factor for IPF.

Purpose of the Study:

• To investigate the efficacy of inhalable hsa-miR-30a-3p-loaded liposomes for treating pulmonary fibrosis.
• To determine if hsa-miR-30a-3p alone can replicate the therapeutic effects of exosomes in IPF.

Main Methods:

• Development of dry powder inhalable liposomes loaded with hsa-miR-30a-3p mimic.
• Administration of inhaled miR-30a and exosomes to mice with bleomycin-induced pulmonary fibrosis.
• Assessment of pulmonary function through six pulmonary function tests.
• Analysis of myofibroblast de-differentiation and alveolar cell remodeling.

Main Results:

• Inhaled miR-30a and exosomes significantly improved pulmonary function in treated mice.
• Both treatments promoted the de-differentiation of profibrotic myofibroblasts.
• miR-30a specifically targets myofibroblast de-differentiation via the CNPY2/PERK/DDIT3 pathway.
• Exosomes promoted reparative alveolar cell remodeling and vascular healing through TGF-β signaling downregulation.

Conclusions:

• Inhaled hsa-miR-30a-3p-loaded liposomes represent a promising new therapeutic strategy for IPF.
• This approach effectively represses myofibroblast epithelial-mesenchymal transition, attenuating fibrosis.
• The study validates hsa-miR-30a-3p as a key therapeutic miRNA for pulmonary fibrosis treatment.